The us pharmaceutical industry outlook to 2016 sample report

3,075
-1

Published on

The present report gives a detailed analysis on the Pharmaceutical market in the US covering various aspects such as market size of the pharmaceutical industry, market segmentation by Branded and Generic drugs, and Prescribed and OTC drugs and Biologics and specialty drugs segments.

1 Comment
0 Likes
Statistics
Notes
  • Be the first to like this

No Downloads
Views
Total Views
3,075
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
70
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

The us pharmaceutical industry outlook to 2016 sample report

  1. 1. TABLE OF CONTENTS1. The US Pharmaceutical Industry Introduction2. The US Pharmaceutical Market Size, 2005-20103. Top 50 Pharmaceutical Drugs in the US4. The US Regulations Pertaining to the Pharmaceutical Industry General Overview Health Care Reform Patent5. The US Pharmacy Distribution and Reimbursement System6. The US Pharmaceutical Market Segmentation 6.1. By Generic and Branded Drugs, 2005-2010 6.1.1. Generic Drugs Competitive Landscape, 2011 6.2. By Prescribed and Over the Counter Drugs (OTC), 2005-2010 6.2.1. Prescribed Drugs Market Segmentation, 2006-2010 6.2.1.1. Top Therapeutic Classes in the US by Prescriptions Dispensed and Spending, 2006-2010 6.2.1.2. The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, 2005-2010 6.2.1.3. The US Prescription Drug Competitive Landscape, 2010 6.2.1.4. Top US Pharmacies by Total Prescription Revenues, 2011 6.2.2. OTC Drugs Market Segmentation, 2007-2010 6.3. The US Biologics/Biopharmaceutical Market 6.3.1. The US Biologics/Biopharmaceutical Market Size By Value, 2006-2011 6.3.2. Top Selling Biologic Drugs, 2010 6.3.3. Top US Biopharmaceutical Companies Market Share, 2011 6.3.4. Biologic Drugs Future Projections, 2012-2016 6.4. The US Specialty Drugs Market
  2. 2. 7. The US Pharmaceutical Industry Trends and Developments Rising Expenditure on Biopharmaceutical Research and Development Expanding Generic Drug Market Rising Prescription Drug Prices Rise in Shortage of Drugs Rising M&A Activities in the US Pharmaceutical Market8. Exports and Imports of Pharmaceticals and Medicines in the US, 2005-20109. The US Pharmaceutical Industry Competitive Landscape, 201110. The US Pharmaceutical Industry Future Outlook and Projections, 2011-2015 10.1. Cause and Effect Relationship Between Industry Factors and the US Pharmaceutical Market Prospects11. Major Pharmaceutical Company Profiles 11.1. Pfizer Inc. Company Overview Business Strategies Financial Performance 11.2. Merck & Co. Company Overview Business Strategies Financial Performance 11.3. Novartis Company Overview Business Strategies Financial Performance 11.4. AstraZeneca Company Overview Business Strategies
  3. 3. Financial Performance 11.5. GlaxoSmithKline Company Overview Business Strategies Financial Performance12. Macro Economic and Industry Indicators: Current and Projections 12.1. Population, 2005-2015 12.2. Inpatient Admissions & Outpatients Visits, 2005-2010 12.3. Number of People with Health Insurance 12.4. Prescription Drug Price index, 2005-2015 12.5. Personal Disposable Income13. Appendix 13.1. Market Definition 13.2. Abbreviations 13.3. Research Methodology Data Collection Methods Approach Variables (Dependent and Independent) Multi Factor Based Sensitivity Model Final Conclusion 13.4. Disclaimer
  4. 4. LIST OF FIGURESFigure 1: The US Pharmaceutical Market Size by Total Sales, in USD Billion, 2005-2010Figure 2: The US Pharmacy Distribution and Reimbursement SystemFigure 3: The US Pharmaceutical Market Segmentation by Branded and Generic Drugs on theBasis of Revenue, in Percentage, 2005-2010Figure 4: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on theBasis of Revenue, in Percentage, 2005-2010Figure 5: The US Prescription Drug Competitive Landscape by Number of PrescriptionsPercentage, Million, 2010Figure 6: The US Biopharmaceuticals Market Size by Value in USD Billion, 2006-2011Figure 7: Market Share of the Major Biopharmaceutical Companies in the US on the Basis ofRevenue, Percentage, 2011Figure 8: Future Projections of US Biologic Drug Sales, USD Billion, 2012-2016Figure 9: Top Specialty Categories by Percent Contribution to Net Specialty Costs, 2010Figure 10: The US Expenditure on Biopharmaceutical Research and Development, in USDBillion, 2005-2010Figure 11: Average Drug Prices for All Prescription, Branded Drugs and Generic Drugs, USD,2005-2010Figure 12: Number of M&A Deals in the US Pharmaceutical Sector by Value, in Number, 2010Figure 13: The US Pharmaceutical Industry Future Projections in Terms of Sales, in USDBillion, 2011-2015Figure 14: The US Pharmaceutical Companies’ Market Share in Percentage, 2011Figure 15: Pfizer Biopharmaceutical Sales in the US, in USD Billion, 2005-2011Figure 16: Merck Pharmaceutical Drugs Sales in the US, in USD Billion, 2009-2011Figure 17: Novartis Drug Revenue in the US, in USD Billion, 2005-2011Figure 18: AstraZeneca Pharmaceutical Drug Sales, in USD Billion, 2005-2011Figure 19: GlaxoSmithKline Pharmaceutical Drug Sales in the US, in USD Billion, 2007-2011........................................................................................................Error! Bookmark not defined.Figure 20: The US Population in Million, 2005-2015
  5. 5. Figure 21: Inpatient Admissions in Community Hospitals in the US, in Million, 2005-2010Figure 22: Outpatient Visits in Community Hospitals in the US, in Million, 2005-2010Figure 23: Total Number of People in the US with Health Insurance, in Million, 2005-2010Figure 24: The US Prescription Drug Price Index, 2005-2015Figure 25: Personal Disposable Income in the US, in USD Billion, 2005-2015
  6. 6. LIST OF TABLESTable 1: Sales of the Top 50 Drugs in the US, in USD million, 2005-2010Table 2: Sales of the Top 50 Drugs in the US in Million Units, 2005-2010Table 3: Major Provisions/ Amendments in the ACA and their ImpactsTable 4: The US Pharmaceuticals Market Segmentation by Branded and Generic Drugs on theBasis of Revenue, in USD Billion, 2005-2010Table 5: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on theBasis of Revenue, in USD Billion, 2005-2010Table 6: Top 10 Prescribed Drugs in the US by Dispensed Prescriptions, in Million, 2006-2010Table 7: Top 10 Therapeutic Classes in the US by Dispensed Prescriptions, in Million, 2006-2010Table 8: Top 10 Therapeutic Classes in the US by Spending, in USD Billion, 2006-2010Table 9: The US Retail Prescription Drug Sales Segmentation in Volume by Number ofPrescriptions in Type of Sales Outlet, Million, 2005-2010Table 10: The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, USDBillion, 2005-2010Table 11: Top US Companies’ by Number of Prescriptions Dispensed, Million, 2010Table 12: Top US Pharmacies by Estimated Total Prescription Revenues, USD Billion, 2011Table 13: OTC Drugs Segmentations by Medicine Category, USD Million, 2007-2010Table 14: The US Sales of Top Selling Global Biologic Drugs, USD billion, 2010Table 15: Top US Companies’ by Sales of Biopharmaceutical Drugs, USD Billion, 2011Table 16: Specialty Categories, Average Cost in USD and Relative Available Medications, 201Table 17: Top Pharmaceutical Drugs Losing Patent Protection in 2011 and 2012Table 18: The US Pharmaceuticals and Medicines Exports, USD Million, 2005-2010Table 19: The US Pharmaceuticals and Medicines Imports, USD Million, 2005-2010Table 20: US Pharmaceutical Companies’ Sales USD Billion, 2011Table 21: The US Pharmaceutical Industry Future Projections in Terms of Sales by Prescribedand OTC drugs, and Branded and Generic Drugs, USD Billion, 2011-2015
  7. 7. Table 22: Cause and Effect Relationship between Industry Factors and the US PharmaceuticalsIndustry ProspectsTable 23: Pfizer’s Product Patent Expiration YearTable 24: Top Selling Pfizer’s Biopharmaceutical Products in the US in USD Million, and theirRevenue Contribution in Percentage, 2011Table 25: Merck’s Top Pharmaceutical Drug Sales in US, USD Million, 2010-2011Table 26: Novartis’ Revenue Segmentation by Pharmaceutical and Sandoz Division in the US,USD Billion, 2005 - 2011Table 27: Novartis’ Top Pharmaceutical Drug Sales in the US, USD Million, 2011Table 28: Astra Zeneca’s pharmaceutical drug sales in the US by product and Therapeuticcategory, in USD Million, 2011Table 29: GlaxoSmithKline’s Top Selling Pharmaceutical Drugs in the US, in USD Million,2011Table 30: Demographic Distribution of Population in US on the basis of Age, in Million, 2009-2012Table 31: Correlation Matrix of the US Pharmaceutical MarketTable 32: Regression Coefficients Output
  8. 8. THE US PHARMACEUTICAL MARKET SIZE, 2005-2010The US Pharmaceutical market is the largest pharmaceutical market in the world which hasregistered a marginal slowdown in the growth rate over the period. The slowing growth rate canbe attributed to an increasing number of drugs losing its patent security and surrogated bygeneric equivalents. In terms of sales value, the US pharmaceutical industry has recordedconsistent growth at a 5 year CAGR of ~ over the period. The sales of Pharmaceuticals in the USgrew from...Figure: The US Pharmaceutical Market Size by Total Sales, in USD Billion, 2005-2010 330.0 320.0 310.0 300.0 290.0 280.0 270.0 260.0 250.0 240.0 2005 2006 2007 2008 2009 2010THE US REGULATIONS PERTAINING TO THEPHARMACEUTICAL INDUSTRYGENERAL OVERVIEWPharmaceutical companies are subject to the national, state and local laws and regulations of thecountry in which they operate. In the US, the Food and Drug Administration (FDA) has authorityover the biopharmaceutical products and also manages the requirements covering the testing,safety, effectiveness, manufacturing, labeling, marketing, advertising and post−marketingmonitoring of these biopharmaceutical products. Additionally, these companies are also subjectto the control of ….
  9. 9. HEALTH CARE REFORMPatient Protection and Affordable Care Act, as revised by the Health Care and EducationReconciliation Act was signed into law on March 23, 2010. The provisions of this Affordablecare act (ACA) will be effective in various dates over the period.Companies are bound to pay ……..Table: Major Provisions/ Amendments in the ACA and their ImpactsProvision Amendment Impact    THE US PHARMACEUTICAL MARKET SEGMENTATIONBY GENERIC AND BRANDED DRUGS, 2005-2010Branded drugs hold the major market share in the total pharmaceutical drugs sales in the US. In2010, branded drugs accounted for ~ of the total drugs sold, but this market share decreased overthe period from ~ in 2005. The sales of branded drugs grew from USD ~ billion in 2005 to USD~ billion in 2010 at a CAGR of ~. Generic drugs, which showcased a growth in the market shareover the…
  10. 10. Figure: The US Pharmaceutical Market Segmentation by Branded and Generic Drugs onthe Basis of Revenue, in Percentage, 2005-2010 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2005 2006 2007 2008 2009 2010 Generic Drugs Branded DrugsFigure: The US Pharmaceuticals Market Segmentation by Branded and Generic Drugs onthe Basis of Revenue, in USD Billion, 2005-2010Sales (USD Billion) 2005 2006 2007 2008 2009 2010Branded Drug SalesGeneric Drug SalesBY PRESCRIBED AND OVER THE COUNTER DRUGS (OTC), 2010Prescribed drugs commanded ~ share of the total pharmaceutical sales in the US in 2010 whichhas grown from ~ in 2005. The sales of prescribed drugs has grown from USD ~ billion in 2005to USD ~ billion in 2010 at a 5 year CAGR of ~. OTC drugs on the other hand hold …
  11. 11. Figure: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs onthe Basis of Revenue, in Percentage, 2005-2010 100.0% 90.0% 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 2005 2006 2007 2008 2009 2010 OTC Drugs Prescribed drugsTable: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs onthe Basis of Revenue, in USD Billion, 2005-2010Sales (USD Billion) 2005 2006 2007 2008 2009 2010Prescribed Drug SalesOTC Drug SalesTHE US RETAIL PRESCRIPTION DRUG SALES SEGMENTATION BY TYPE OFSALES OUTLETTraditional chains are the largest sales medium for prescription drugs sales accounting for ~ ofthe total sales. In 2010, ~ million prescription drugs worth USD ~ billion were sold viatraditional chains, which have grown from ~ billion worth USD ~ billion in 2005 at a 5 yearCAGR of 3.1%. Traditional chains accounted for ~ of the revenue generated from totalprescription drugs sold, and ~ of the total prescriptions dispensed in 2010. Independent storesare the second largest sales outlet for…Table: The US Retail Prescription Drug Sales Segmentation in Volume by Number ofPrescriptions in Type of Sales Outlet, Million, 2005-2010Sales outlet 2005 2006 2007 2008 2009 2010Traditional chain
  12. 12. IndependentMass merchantSupermarketsMail OrderNumber of prescriptionsTable: The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, USDBillion, 2005-2010Sales outlet 2005 2006 2007 2008 2009 2010Traditional chainIndependentMass merchantSupermarketsMail OrderRetail SalesTHE US BIOLOGICS/BIOPHARMACEUTICAL MARKETTHE US BIOLOGICS/BIOPHARMACEUTICAL MARKET SIZE BY VALUEBiologic drugs are gradually increasing their share over the period. These proteins based drugs,mainly produced using Recombinant DNA technology, and are used increasingly to treatnumerous conditions. The Biopharmaceutical Market is booming in the US. Biological drugs aregenerally more expensive than the conventional drugs thus acting as key revenue earners forproducers. The top categories of biologic drugs in terms of sales are …
  13. 13. Figure: The US Biopharmaceuticals Market Size by Value in USD Billion, 2006-2011 70.0 60.0 50.0 40.0USD Billion 30.0 20.0 10.0 0.0 2006 2007 2008 2009 2010 2011IMPORTS AND EXPORTS OF PHARMACETICALS ANDMEDICINES IN THE USThe imports of Pharmaceuticals and medicines have increased over the period of 5 years at aCAGR of ~ to USD ~ billion in 2010. Pharmaceutical Preparations accounted for ~ of the totalimports, contributing USD ~ billion in 2010 which has grown from USD ~ billion in 2005 at aCAGR of ~. Medical and botanical drugs and vitamins constituted ~ of the totalTable: The US Pharmaceuticals and Medicines Exports, USD Million, 2005-2010NAICSCode Exports (USD Million) 2005 2006 2007 2008 2009 2010Table: The US Pharmaceuticals and Medicines Imports, USD Million, 2005-2010NAICSCode Imports (USD Million) 2005 2006 2007 2008 2009 2010
  14. 14. THE US PHARMACEUTICAL INDUSTRY FUTUREOUTLOOK AND PROJECTIONS, 2011-2015The US Pharmaceutical industry is among the largest pharmaceutical industries in the world andis likely to be the leader in the future, ceteris paribus. But over the period, the development ofnew and innovative blockbuster pharmaceutical drugs has been slowing down as the number ofblockbuster drugs are losing patents over the period and are being threatened by relative genericdrugs. The market share of generic drugs is increasing….…. The US pharmaceutical industry is expected to grow over the period at a CAGR ~ withprojected sales of USD ~ billion in 2015. It is estimated that the research and developmentproductivity will increase and will trigger the growth in the market. Additionally the companieswill focus on …Figure: The US Pharmaceutical Industry Future Projections in Terms of Sales, in USDBillion, 2011-2015 450.0 400.0 350.0 Sales (USD Billion) 300.0 250.0 200.0 150.0 100.0 50.0 0.0 2011 2012 2013 2014 2015Table: The US Pharmaceutical Industry Future Projections in Terms of Sales byPrescribed and OTC drugs, and Branded and Generic Drugs, USD Billion, 2011-2015Drug Segmentation 2011 2012 2013 2014 2015Prescribed and OTCPrescribed Drugs
  15. 15. OTC Drugs % share of Prescribed drugs % share of OTC drugs Branded and Generic Branded Drugs Generic Drugs % share of Branded drugs % share of Generic drugs CAUSE AND EFFECT RELATIONSHIP BETWEEN DEPENDENT AND INDEPENDENT FACTORS PREVAILING IN THE US PHARMACEUTICALS INDUSTRY Table: Cause and Effect Relationship between Industry Factors and the US Pharmaceuticals Industry ProspectsIndustry Factors Market Impact CommentsIncreasing price of Branded drugs Rising M&A activities and ConsolidationAdvanced Technology and competitive edge in R&D andManufacturingGovernment regulations and SupportShortage of Drugs Expansion into Emerging Markets Rising Chronic Diseases 
  16. 16. THE US PHARMACEUTICAL INDUSTRY COMPETITIVELANDSCAPEThe US pharmaceutical industry witnessed revenues worth of USD ~ billion in 2011. Pfizer isthe largest company with a market share of ~ and sales of USD ~ billion in 2011. Pfizer’sblockbuster drug, Lipitor played a major role in helping the company secure its number oneposition. With ~% market share in …Figure: The US Pharmaceutical Companies’ Market Share in Percentage, 2011 2011Source: Company ReportsTable: The US Pharmaceutical Companies’ Sales USD Billion, 2011Company 2011 Sales (USD Billion)PfizerMerckBristol-Myers SquibbRocheAstraZenecaNovartis
  17. 17. Johnson & JohnsonSanofiAmgenEli LillyGlaxoSmithKlineAbbott LaboratoriesTeva PharmaceuticalsOthersTotal US Pharmaceutical SalesPFIZER INC.FINANCIAL PERFORMANCEPfizer has shown a fluctuated growth over the period. The company witnessed sales of USD ~billion in 2011 which has grown from USD ~ billion in 2005 at a CAGR of ~ The companyrecorded decline of ~, ~ and ~ in 2007, 2008 and 2011 respectively. The 2011 revenue decreasewas due to the …Figure: Pfizer Biopharmaceutical Sales in the US, in USD Billion, 2005-2011 30.0 25.0 Sales (USD Billion) 20.0 15.0 10.0 5.0 0.0 2005 2006 2007 2008 2009 2010 2011
  18. 18. DISCLAIMERNo part of this manual or any material appearing may be reproduced, stored in or transmittedon any other Web site without written permission of AM Mindpower Solutions and any paymentsof a specified fee. Requests to republish any material may be sent to us.For more information please refer to the below mentioned link:http://ammindpower.com/report.php?A=256ORContact at:info@ammindpower.com

×